A US-based firm has developed the world's first COVID-19 test that can be completed using a camera phone. The test is currently awaiting emergency approval from the Food and Drug Administration in the United States.
The tests can be completed at home, with a lateral flow test and a camera phone. Gauss, the Menlo Park, CA based company that has developed the technology, states that it can produce up to 30 million tests per month.
The process employs AI technology and an encrypted smartphone app to verify test results, which can be then be sent to health agencies.
Patients are sent a testing kit, which they use to take a nasal swab and then complete the included antigen test. The app will prompt the user to scan the results after 15 minutes, and the artificial intelligence-based system will provide results to patients within seconds.
The app contains a video with step-by-step instructions, to help users complete the "easy-to-use" test from home, with the actual phone portion of the test being there to minimize user errors and send the results on to health agencies.
"The new at-home testing solution, which is currently awaiting Food and Drug Administration (FDA) Emergency Use Authorization (EUA), will offer affordable access to cutting-edge testing technology developed by Gauss, a leader in computer vision-aided healthcare diagnostics," states a company press release (via iMore).
"Once authorized, it will be the first rapid COVID-19 test that can be fully performed using only a smartphone and a lateral flow assay (similar to an at-home pregnancy test), without involving a laboratory, a telemedicine visit or any specialized electronics. Last month, Gauss produced its first 1.5 million tests, which will be available for immediate distribution when the test receives EUA from the FDA, and the company has the capability to produce up to 30 million tests per month."
The use of smartphones as medical tools is becoming increasingly common, with the cameras being employed in apps that are capable of detecting Malaria and early kidney disease.